Business Wire

Hempyre Holdings Ltd. Launches Global Platform for Branded Hemp-Formulated Consumer Packaged Goods

28.4.2020 13:00:00 EEST | Business Wire | Press release

Share

Hempyre Holdings Ltd. (“Hempyre” or the “Company”) is pleased to announce the launch of a global distribution platform of branded hemp-formulated consumer packaged goods focused on beauty, beverage, and wellness.

Headquartered in London, Hempyre has agreed to acquire CMLM Holdings, Inc., dba QIND, a U.S.-based provider of hemp-formulated wellness and beauty products featuring CBD and CBG. Hempyre has also agreed to acquire select beverage and topical brands in the United Kingdom and China and has actively been hiring local executive talent.

Hempyre’s management team is led by Mr. Shannon Soqui, Chief Executive Officer, and Mr. Jason Roth, Chief Strategy Officer. Mr. Soqui was formerly the Chief Executive Officer of QIND, and Mr. Roth was the Co-Founder, Chairman, and Chief Executive Officer of Mile High Labs until October 2019.

Mr. Soqui has 25 years of experience advising and financing emerging growth companies in disruptive markets, including retail and consumer packaged goods. Mr. Soqui has worked exclusively in the cannabis and hemp industry since 2014, after a successful 25-year career in Silicon Valley as an investment banker with firms such as Credit Suisse and UBS, a securities lawyer with Brobeck, Phleger & Harrison, and a CPA with KPMG.

“As hemp becomes legal in more countries, we see a tremendous opportunity for a branded consumer packaged goods platform focused on beauty, beverages, and wellness in selected markets,” said Mr. Soqui. “With a focus on high quality products that are legally compliant, tested and safe, and developing a broad global distribution platform, both wholesale and online, we believe that we will be well positioned to develop brand recognition globally.”

Mr. Roth has 25 years of experience owning consumer packaged goods and medical device companies that have operated internationally, and is respected for his strategic leadership and disciplined approach to driving revenue.

“The European beverage market has very attractive business and financial dynamics given the recent legalization of hemp-infused beverages in the United Kingdom and other parts of Europe,” said Mr. Roth. “Asia is also a very attractive market for us. Our partnerships with major distribution partners and key opinion leaders will enable us to reach hundreds of millions of consumers very effectively.”

About Hempyre

Hempyre is an emerging global provider of branded hemp-formulated consumer packaged goods focused on Beauty, Beverage, and Wellness. Hempyre’s Beauty product line focuses on consumer hemp-formulated topical solutions to protect and rejuvenate their skin and body. Hempyre’s Beverage product line focuses on consumers who are looking for healthy ways in which to consume hemp-formulated distilled alcoholic and non-alcoholic spirits, sparkling and live sodas, pressed juices, water, and other ready-to-drink offerings. Hempyre’s Wellness product line focuses on consumers looking for hemp-derived CBD and CBG alternatives to treat anxiety, inflammation, insomnia, pain, or to manage and regulate their overall health.

Hempyre’s core strategy focuses on product branding and distribution in Europe, China, the U.S., and the Asia-Pacific region, while outsourcing most aspects of raw material production and finished goods manufacturing. Hempyre currently has 11 brands with more than 150 product SKUs across its three product segments. Hempyre’s hemp-formulated products are non-psychoactive and are made from high quality strains of hemp oil extracts containing either pure CBD or CBG, or combined with a broad or full spectrum of hemp compounds, including other cannabinoids and terpenes.

Hempyre’s primary operating subsidiaries are located in London, England, and Portland, Oregon, with additional staff in Hong Kong, and Auckland, New Zealand. With its licenses and permits, and given the emerging legalization of hemp-formulated products, Hempyre exports selected hemp-formulated CBD and CBG products from the U.S. to selected developed countries globally. Hempyre’s U.S. operations are licensed as a hemp handler by the Oregon Department of Agriculture, and act as a base for distribution throughout the U.S., with shipment enabled by the USPS. For raw material production and finished goods manufacturing, Hempyre’s strategy is to rely on farmers and concentrate processors in the U.S. for raw materials, and GMP-certified co-packers and white-label manufacturers for finished goods assembly or production. Hempyre’s hemp-formulated CBD and CBG products are distributed through its global network of distributors and wholesalers, its own and third-party owned e-commerce websites, Company-leased storefronts, and a variety of brick and mortar mainstream retailers. For more information visit www.hempyre.com.

Strategic Opportunities:

Hempyre is interested in discussing potential acquisitions of branded product and/or distribution companies in the Beauty, Beverage, or Wellness segments that could infuse CBD and CBG into their products.

Please contact jason@hempyre.com for information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

U.S. Media Contact:
Mr. Erik Ritchie
media@hempyre.com
888-743-6797

U.K. Media Contact:
Mr. William Draper
media@hempyre.com
+44 (0) 800 020 9806

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FuzeBox AI Named Founding Co-Author of SPUR Coalition Technical Committee on Verifying AI Content Use5.10.2026 16:00:00 EEST | Press release

FuzeBox AI has been named by the SPUR Coalition, an international nonprofit of 37 news and media organizations, as one of four founding co-authors of its Evidence Profile Technical Committee, adopted Sept. 2, 2026, to draft an evidence profile for SPUR's Content Telemetry standard: a way for publishers to verify AI usage reports without depending on the reporting company's cooperation. Under SPUR's current standard, AI companies self-report their content use. A company that skips reporting leaves no record, and publishers can't check what they do receive. On July 10, 2026, FuzeBox proposed its Verified Provenance Telemetry Standard (VPTS): publishers seed content with detectable markers, then verify their appearance in AI outputs via an auditable ledger, with no change to SPUR's standard. Within 48 hours, three organizations filed related proposals: ProRata on usage magnitude, Encypher CEO Erik Svilich on the verification question FuzeBox raised, and LicenseFoundry on portable proof of

Mary Kay Introduces the K-Beauty Texture Edit5.10.2026 15:02:00 EEST | Press release

Mary Kay Inc.,the iconic beauty giant announced today the launch of the K-Beauty Texture Edit, aspecial-edition skin care collection available while supplies last. The collection builds on the momentum of the company's largest consumer-facing global brand platform, Beauty Is More Beautiful Shared™ which launched in September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005600130/en/ Mary Kay's Special Edition K-Beauty Texture Edit is a trend-forward collection which includes three Korea-made products: the Mary Kay® Melt-In Cleansing Balm, Mary Kay® Snail Gel Face Patches and Mary Kay® Collagen Moisturizing Gel. (Image Credit: Mary Kay Inc.) Inspired by Korea's globally influential skin care and self-care philosophy designed to bring playful textures, innovative ingredients, and elevated beauty experiences, the K-Beauty Texture Editwas designed to resonate with a global cultural beauty movement captivating the next gene

GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.5.10.2026 15:00:00 EEST | Press release

GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005273717/en/ SOFIE Biosciences has 15 CMO sites across the U.S., manufacturing PET radiopharmaceutical products The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical ‘final mile’ of U.S. PET radiopharmaceutical supply, while also enabling PDx to participate in other high growth areas outside its own product portfolio. With a U.S. network of 15 CMO sites operating 21 cyclotrons, and a theranostics

Henkell Freixenet Strengthens Premium Dealcoholized Sparkling Wine Production with Solos' Patented Aroma Recovery System5.10.2026 14:24:00 EEST | Press release

Henkell Freixenet is expanding its premium dealcoholized sparkling wine production capabilities through the deployment of Solos Technology's patented Aroma Recovery System (ARS) at its Wiesbaden production site, the Group’s expertise centre for alcohol-free production. The installation represents a significant investment in next-generation dealcoholized sparkling wine production, helping preserve the natural aroma and sensory identity of the original wines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005959301/en/ Fürst von Metternich Riesling Alcohol-free on the bottling line, one of the first products in Henkell Freixenet’s portfolio developed in collaboration with Solos Technology. The project combines Henkell Freixenet's longstanding winemaking expertise with Solos' proprietary dealcoholization and patented aroma recovery technology. With 30 years of experience in producing alcohol-free sparkling wines, Henkell Fre

Croma-Pharma Expands Its Portfolio in Canada With saypha ® lips Lidocaine and Exprecell™5.10.2026 14:12:00 EEST | Press release

Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they give practitioners options across both aesthetic and regenerative treatment categories, from a single trusted source. "With saypha® lips Lidocaine and Exprecell™, we're giving Canadian practitioners a wider set of tools for facial aesthetics and regenerative treatments, each held to the same standard of precision and safety," said Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. Renellence has distributed Croma's Saypha® hyaluronic acid filler range in Canada since October 2025, alongside medical education and training for Canadia

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye